Published Paper Details:

Objective: To analyze the effectiveness of naftopidil versus tamsulosin as a therapy for patients with LUTS. Methods: The study was conducted by searching for published studies using the Cochrane Central Register of Controlled Trial search engine, PUBMED, Google Scholar, and Science-Direct. Randomized Controlled Trials (RCTs) that compare naftopidil with tamsulosin as therapy for Lower Urinary Tract Symptoms in BPE patients were identified. A systematic review carried out using protocols The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Results: Five RCTs were included in the IPSS Storage outcome. Naftopidil was not significant (mean difference (MD) -0.56, 95% Confidence Interval (CI) -1.16-0.04, P = 0.07). Three RCTs studies matched the IPSS Voiding outcome (MD -0.28, 95% CI -1.45-0.89, P = 0.63). Seven RCTs studies according to Qmax outcome (MD -0.66.95% CI -1.54-0.22, P = 0.13), Seven RCTs studies according to PVR outcome (MD 1.75, 95% CI -0.49-3.9, P = 0.14). Four RCTs had a low risk of bias, four RCTs unclear of bias, one RCTs had a high risk of bias. Conclusion: Naftopidil did not have a significant difference compared to tamsulosin in reducing IPPS storage, IPSS voiding, decreasing PVR, increasing Qmax.